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TranscriptionThe control of cell proliferation by microRNAs (miRNAs) is well established and the alteration of these small,
non-coding RNAsmay contribute to tumor development by perturbing critical cell cycle regulators. Oncogenic
miRNAs may facilitate cell cycle entry and progression by targeting CDK inhibitors or transcriptional
repressors of the retinoblastoma family. On the other hand, tumor suppressor miRNAs induce cell cycle arrest
by downregulating multiple components of the cell cycle machinery. Recent data also suggest that miRNAs act
co-ordinately with transcriptional factors involved in cell cycle regulation such as c-MYC, E2F or p53. These
miRNAs not only can potentiate the function of these factors but they may also limit the excessive translation
of cell cycle proteins upon mitogenic or oncogenic stimuli to protect cells from replicative stress. The
implications of these regulatory networks in cell proliferation and human disease are discussed.tigaciones Oncológicas (CNIO),
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The cell division cycle is regulated through multiple molecular
pathways and checkpoints. Most adult mammalian cells are quiescent
(i.e. out of the cell cycle) and re-entry into the cell cycle requires the
inactivation of the retinoblastoma protein (pRB) and the transcription
of genes required for DNA replication during S (for DNA Synthesis)
phase or chromosome segregation during mitosis (M phase) [1]. Most
mitogenic pathways result in the transcriptional induction of D-type
cyclins and the subsequent activation of cyclin-dependent kinases
(CDKs) such as CDK4 and CDK6 (Fig. 1). These kinases, as well as other
family members, phosphorylate and inactivate pRB, a transcriptional
repressor that inhibit E2F transcription factors and recruit chromatin
remodeling complexes that lead to the repression of targeted genes
[1]. Upon mitogenic stimuli, the active CDK4/6-cyclin D complexes
inactivate pRB, leading to the E2F-dependent transcription of cell
cycle genes. Once the DNA replication machinery is expressed, cells
are committed to S-phase and progression throughout the cell cycle is
monitored by a variety of checkpoints that are able to arrest or delay
the cell cycle in the presence of DNA damage, defective replication or
mitotic aberrancies. For instance, a variety of anti-proliferative signals
leads to the expression of several CDK inhibitors, such as themembersof the INK4 (p16INK4a, p15INK4b, p18INK4c or p19INK4d) or Cip/Kip
(p21Cip1, p27Kip1 and p57Kip2) families [1,2].
Once the genome is replicated during S-phase, cells are ready to
segregate the two genomes into two daughter cells during mitosis.
Since most proteins required for mitosis have been synthesized in the
earlier phases of the cell cycle, the regulation of the G2/M transition
and mitotic exit mostly depends on post-translational mechanisms.
CDK1, when bound to A- or B-type cyclins, is a major kinase required
for mitotic entry through the phosphorylation of a signiﬁcant number
of cytoplasmic and nuclear substrates [3]. Other kinases required for
the duplication and maturation of centrosomes include members of
the Polo-like kinases (PLK) and Aurora kinases [4]. These proteins, as
well as many other regulators involved in the cytoplasmic and nuclear
changes required for mitosis, control the establishment of a bipolar
spindle and the orderly segregation of chromosomes into the two
daughter cells. Mitotic exit (i.e. reformation of two interphasic nuclei)
requires the elimination of a signiﬁcant number of cell cycle
regulators by proteolysis. This is mediated at least partially by the
Anaphase-promoting complex (APC/C), an E3 ubiquitin ligase that
targets multiple cell cycle proteins with ubiquitin for proteasome-
dependent degradation [5,6].
Since cell cycle progression requires the presence and activity of
multiple proteins that are not expressed in quiescent cell, the
regulation of the levels of these proteins is a central issue in the
understanding of the control of the cell cycle and its deregulation in
human disease. For instance, genetic mutations leading to the
overexpression of cyclins or the elimination of several CDK inhibitors
Fig. 1. An overview to cell cycle control by microRNAs. Some interactions have been omitted for clarity. let-7 (let-7a-f) and miR-15 (miR-15, miR-16 and miR-195) indicate several
members of the corresponding family. Most miRNA names correspond to mature forms whereas miRNAs clusters are shown in italics. miRNAs with proliferative potential are shown
in red whereas antiproliferative miRNAs are in blue. S, S-phase; M, Mitosis; G1 and G2 indicate transition phases of the cell cycle whereas G0 indicate quiescent cells. Please note that
most of these interactions come from luciferase reporter assays and need to be validated using additional methods.
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cancer, suggesting that the proper control of the protein levels of
these regulators is crucial for cell division [1]. As indicated above, the
levels of cell cycle regulators may be controlled by post-transcrip-
tional mechanisms. Among them, the central role of proteolysis in the
timely elimination of cell cycle regulators is well established [6–8].
Recent evidences suggest that microRNAs (miRNAs) may also control
the levels of multiple cell cycle regulators and may therefore control
cell proliferation. In fact, deregulation of miRNAs may also lead to
proliferative diseases such as cancer by altering the protein levels of
critical oncogenes or tumor suppressor genes [9,10]. Not surprisingly,
the expression of miRNAs is controlled by typical cell cycle pathways
suggesting that miRNAs should also be considered as important
players of the mammalian cell cycle.
2. Control of the cell cycle by miRNAs
miRNAs are a class of endogenously expressed, noncoding RNAs
that control the stability and translation of protein-coding mRNAs[11,12]. These small (18–25 nucleotides) RNAs are incorporated into
miRNA–protein complexes that bind the 3′ untranslated region
(3′UTR) of target mRNAs [13]. These target regions display partial
complementary homology with miRNAs and the binding of miRNA–
protein complexes can be avoided by mutating critical target residues
in the 3′UTR of target transcripts. The corresponding nucleotides in
the mature miRNA sequence that display homology with the target
mRNAs are known as the ‘seed’ sequence. The binding of miRNA–
protein complexes to mRNAs may inhibit translation or destabilize
target transcripts resulting in the downregulation of the protein
encoded by the respective mRNA [12]. Bioinformatics estimates
suggest that more than 30–60% of the human genome may be
subjected to regulation by miRNAs [12,14]. By modulating the
expression of target transcript, miRNAs can therefore affect many
different signaling pathways and cellular processes such as
proliferation, differentiation or apoptosis [15–17]. No wonder, the
control of critical targets by miRNAs has multiple implications in
cancer [10,18] and miRNAs can also considered as cancer targets
[19,20].
594 M.J. Bueno, M. Malumbres / Biochimica et Biophysica Acta 1812 (2011) 592–6012.1. Control of the G1/S transition by miRNAs
One of the ﬁrst solid links between miRNAs and cell cycle
regulation was established in the analysis of the anti-proliferative
potential of the mir-15a-16-1 cluster. This cluster expresses two
mature miRNAs, miR-15a and miR-16, that share a similar seed
sequence and therefore belong to the same miRNA family (miR-15
family). Interestingly, the mir-15a-16-1 cluster was identiﬁed as the
target of some speciﬁc chromosome aberrations in chronic lympho-
cytic leukemia (CLL) patients in the pioneer study that ﬁrst linked
genetic aberrations in miRNA with cancer [21]. This miRNA cluster is
deleted and/or down-regulated in about 70% of CLL [21], as well as in
pituitary adenomas [22] , prostate cancer [23,24] and in gastric cancer
cell line [25], suggesting an important role in tumor development.
The mir-15a-16-1 cluster may induce cell cycle arrest at the G1
phase by targeting critical cell cycle regulators such as CDK1, CDK2
and CDK6 as well as cyclins (D1, D3 and E1) [24,26–28]. In fact, these
major cell cycle kinase complexes are regulated by several other
miRNAs (Fig. 1 and Table 1). Thus, CDK4 or CDK6 mRNAs are also
targeted by miR-24, miR-34a, miR-124, miR-125b, miR-129, miR-137,
miR-195 (another member of the miR-15 family), miR-449 and let-7
family members [29–37]. Several positive regulators of CDK4/6
activity are also targeted by miRNAs such as D-type cyclins or
CDC25A, a phosphatase that eliminates inactivating phosphates in
CDKs (Fig. 1 and Table 1). D-type cyclins are major integrators of
mitogenic signaling as their synthesis is one of the main endpoints of
the RAS/RAF/MAPK pathway as well as other mitogenic routes [38].
The levels of D-type cyclins are downregulated by let-7, miR-15
family, miR-17, miR-19a, miR-20a, and miR-34, [23,32,35,37,39–42].
miR-26a directly downregulates cyclins D2 and E2 and induces a G1
arrest of human liver cancer cells in vitro. AAV-mediated miR-26a
delivery potently suppresses cancer cell proliferation and activates
tumor-speciﬁc apoptosis in vivo, resulting in dramatic suppression of
tumor progression without toxicity [39]. miR-16 andmiR-34a are also
able to downregulate cyclin E [28]. As expected, most of thesemiRNAs
display antiproliferative properties, function as tumor suppressors
and they are inactivated in cancer by different mechanisms (Table 1).
For instance, miR-124 and miR-137 are silenced by hypermethylation
in tumor cells of different origins leading to CDK6 overexpression [43].
The overexpression of CDK/cyclin complexes is likely to result in
increased phosphorylation of pRB thus liberating active E2F factors to
drive G1 progression and S-phase entry.
The ﬁrst study that revealed that E2F is targeted bymiRNAs was by
O'Donnell et al. [44]. These authors showed that E2F1 is negatively
regulated by two miRNAs of the mir-17-92 cluster, miR-17-5p and
miR-20a [see also [45]]. Moreover, the levels of those microRNAs
inversely correlate with E2F1 levels in tumors samples from colon
cancer patients, suggesting that these miRNAs promotemalignancy in
many tissues by rendering cells insensitive to the apoptotic abilities of
E2F1 [46]. In addition to the mir-17-92 cluster, other miRNAs play a
role in cell cycle progression by downregulating E2Fs. E2F1 is
inhibited by miR-149*, miR-330 and miR-331-3p resulting in cell
cycle arrest in prostate and gastric cancer cells [47–49]. E2F3, on the
other hand, is targeted bymiR-125b, miR-210 andmiR-195 [35,50,51]
(Fig. 1 and Table 1).
miRNAs are also able to facilitate cell cycle entry and G1
progression by targeting negative regulators of the CDK4/pRB
pathway. pRB itself is targeted by miR-106a and the overexpression
of this miRNA results in pRB downregulation in cancer cells [52].
Other members of the pRB family, p107/RBL1 and p130/RBL2 are
controlled by two microRNA clusters,mir-290 andmir-17-92 [53–55].
Expression of a single miRNA of the mir-17-92 cluster, miR-17-5p, is
sufﬁcient to drive a proliferative signal in cultured cells [55].
Downregulation of the mir-290 cluster, on the other hand, leads to
increase mRNA leves of RBL2 whose product downregulates DNA
methylase expression leading a signiﬁcant hypomethylation of thegenome. These ﬁndings indicate that miRNAs of the miR-290 family
may have important roles in fundamental processes such as
epigenetic regulation in addition to development and tumorogenesis
[53].
Finally, some cell cycle inhibitors of the INK4 or Cip/Kip families
are also tightly regulated by miRNAs. p16INK4a, a CDK4/6 speciﬁc
inhibitor, is controlled by miR-24 and miR-31 [31,56]. Both miRNAs
are involved in the regulation of cell proliferation and progress
through the cell cycle at least in part by regulating the levels of this
CDK inhibitor. p21Cip1, a p53 target, is a direct target ofmir-17-92 and
miR-106b [57,58]. p27Kip1 and p57Kip2 are controlled by miR-221/222
andmiR-181 [58–60]. Ectopic expression of themir-221-222 cluster is
thought to activate CDK2 and enhance tumor growth by negatively
regulating both p27Kip1 and p57Kip2 [61].
2.2. Entry and progression through mitosis
Although most cell-cycle-targeting miRNAs modulate cell cycle
entry and the G1/S transition, a few examples exist for the role of
miRNAs in later phases of the mammalian cell cycle. Once cells have
duplicated their genome, the control of the cell cycle is mostly driven
by CDK1 in complex with cyclin A or cyclin B (CDK2 is also activated
by A-type cyclins). miR-125b, miR-24 and let-7 miRNAs are able to
downregulate the expression of Cyclin A or Cyclin B [40,51,62]. miR-
195,miR-516-3p andmiR-128a can also downregulateWEE1, a kinase
that function as a negative regulator of the CDK1-Cyclin B complex at
the G2/M transition [63,64]. As described in the previous section, the
control of Cip/Kip CDK inhibitors by miRNAs may also affect mitotic
entry by modulating CDK1 activity.
Not many other examples of miRNAs regulating mitosis exist.
Polo-like kinase 1 (PLK1) is a critical regulator of mitosis at several
levels. This kinase phosphorylates CDC25C, which in turn activates
CDK1-Cyclin B1 complexes, resulting in its translocation into the
nucleus and mitotic entry [65]. miR-100 has been proposed to target
PLK1 mRNA, and downregulation of miR-100 leads to PLK1 over-
expression in naso-pharyngeal cancer cell [66]. Finally, Aurora B
kinase, a protein that functions in the attachment of the mitotic
spindle to the centromeres, has been recently described as a target of
miR-24 which recognizes seedless but highly complementary
sequences in the Aurora B-encoding transcript [62]. Yet, the functional
signiﬁcance of the control of these mitotic proteins by miRNAs
remains mostly unexplored.
3. Cell cycle-dependent regulation of miRNAs
miRNA-encoding genes are transcribed by RNA polymerases II or
III to yield primary transcripts (pri-miRNAs), which are then
processed by the nuclear RNase III Drosha to form stem-loop
structures. These pre-miRNAs are transported to the cytoplasm
where the RNase III Dicer cleaves the double-stranded portion of
the hairpin and generates a double strand RNA that is subsequently
unwound giving rise to the mature miRNA [12,67]. In general,
transcription of miRNAs is thought to be regulated similarly to that
of protein-coding genes.
At least 10% of the human genome is known to be regulated in a
cell-cycle dependent manner [68]. The induction of miRNAs in a cell-
cycle dependent manner has been recently studied in primary
ﬁbroblasts stimulated with serum suggesting a similar ratio of cell-
cycle regulated miRNAs [69,70]. In fact, several miRNAs are known to
be induced or repressed by critical transcription factors that control
the cell cycle (Table 2).
3.1. Transcriptional regulation of miRNAs by MYC
c-MYC is a transcription factor that regulates numerous genes thus
playing an important role in cellular processes such as development,
Table 1
Control of cell cycle regulators by microRNAs and relevance of these small RNAs in cancer.
miRNA Cell cycle regulatora Deregulation in cancerb References
let-7 family CDC25A, CDC34, CDK4, CDK6,
Cyclin A, D1, D2 and D3, c-MYC
Downregulated in leukemias, lymphomas, melanoma, lung, breast, gastric, gastric,
pancreatic, pituitary, ovarian, kidney, prostate and colon cancer, hepatocellular carcinoma,
multiple myeloma.
[37,40,82,112,113,
127,128,141]
miR-15 family
(miR-15, miR-16
and miR-195)
CDC27, CDK6, Cyclin D1, D3 and
E1, E2F3 and WEE1
Downregulated in CLL, DLBCL, multiple myeloma, pituitary adenoma, prostate and
pancreatic cancer
[23,26–28,35,
63,64,69]
mir-17-92 cluster (miR17, miR-18a, miR-19a; miR-20a; miR-19b-1; miR-92-1) and paralogous clusters (mir-106a-92-2 and mir-106b-25)
miR-17 family
(miR17, 20, 106, 93)
Cyclin D1, E2F1, MYCN, p21Cip1
and pRb family
Overexpression in lung and colon cancer, lymphoma, multiple myeloma, medulloblastoma.
Downregulated in melanoma, ovarian and breast cancer
[41,44,45,54,55,57,
58,79,93,117,119]
miR-19a CyclinD1 Deregulated in leukemias, hepatocellular carcinoma, colorectal and lung cancer [42]
miR-25 p57Kip2 Deregulated in glioblastoma, hepatocellular carcinoma, colorectar, gastric, pancreatic and
prostate cancer
[58]
miR-24 AURKB, CDK1, CDK4, Cyclin A2,
Cyclin B, E2F2, MYC, p16INK4a
Deregulated in some leukemias, hepatocellular carcinoma and prostate cancer [31,62]
miR-26a Cyclin D2 and E2 Downregulated in leukemia, Burkitt lymphomas, glioma, pituitary, thyroid, liver, kidney,
ovarian, bladder and breast cancer
[39]
miR-31 p16INK4a, p19INK4d Deregulated in bladder, breast, colorectal, liver, lung, pancreatic and prostate cancer [56]
miR-34a CDK4, CDK6, Cyclin D1, Cyclin
E2, E2F1, E2F3 and c-MYC
Deregulated in CLL, medulloblastoma, neuroblastoma, retinoblastoma, glioblastoma,
colorectal, liver, melanoma, pancreatic, thyroid and prostate cancer
[32,98,104]
miR-100 PLK1 Deregulated in bladder, ovarian, pancreatic, prostate and nasopharyngeal cancer [66]
miR-124a CDK6 Deregulated in ALL, CLL, medulloblastoma, hepatocellular carcinoma and breast, colorectal
and lung cancer
[29,30,142]
miR-125b CDC25A, CDK6, Cyclin A, E2F3 Deregulated in neuroblastoma, medulloblastoma, liver, bladder, breast and prostate cancer [33,51]
miR-128a WEE1 Deregulated in ALL, AML, glioblastoma, pituitary adenomas and breast cancer [63,64]
miR-129 CDK6 Reduced expression in multiple tumor cell lines and primary tumors (medulloblastoma,
undifferentiated gastric cancers, lung adenocarcinoma, endometrial, ovarian and bladder
cancer and colorectal and hepatocellular carcinoma)
[118]
miR-137 CDK6 Deregulated in colorectal cancer and hepatocellular carcinoma [29,30,142]
miR-145 c-MYC Deregulated in leukemias, Burkitt lymphomas, bladder, breast, colorectal, ovarian, gastric,
lung, pancreatic, prostate cancer and hepatocellular carcinoma
[143]
miR-149* E2F1 Neuroblastoma [47]
miR-155 WEE1 Deregulated in leukemias and lymphomas, Pituitary Adenomas, hepatocellular carcinoma,
breast, colorectal, ovarian, lung and pancreatic cancer
[63,64]
miR-181 family
(miR-181a, b
and c)
p27Kip1 Deregulated in leukemias, glioblastoma, hepatocellular carcinoma, breast, colorectal, lung,
pancreatic and prostate cancer
[60]
miR-210 E2F3 Deregulated in leukemias, lymphomas, glioblastoma, breast, kidney, lung, pancreatic,
prostate and ovarian cancer
[50]
miR-221 family
(miR-221 and miR-222)
p27Kip1, p57Kip2 Deregulated in leukemias, glioblastoma, breast, pancreatic, prostate, ovarian, bladder, and
gastric cancer, melanoma and hepatocellular carcinoma
[58,59,121,122,
144,145]
miR-290 cluster p130/RBL2 [53]
miR-330 E2F1 Downregulated in follicular lymphoma, oral squamous cell carcinoma and prostate cancer [48]
miR-331-3p E2F1 Human gastric cancer [49]
miR-322/424, miR-503 CDC25A Deregulated in some leukemias, kidney, ovarian and pancreatic cancer. [146]
miR-449a/449b CDC25A, CDK6 Downregulated in prostate cancer [95]
miR-503 CDC25A Deregulated in retinoblastoma and prostate cancer [146]
miR-504 p53 [147]
miR-516a-3p WEE1 Upregulated in breast cancer and in pituitary adenomas [63,64]
miR-1285 p53 [148]
miR-1296 MCM2 prostate cancer [149]
a Note that most of these interactions have been only validated using luciferase reporter assays.
b Data from the indicated references or from http://www.mir2disease.org/.
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controls the cell cycle by modulating the levels of several regulators of
progression through G1 as well as DNA replication. Deregulated
expression of c-MYC has been detected in a wide variety of human
cancers, including breast and colon, and is often associated with
aggressive, poorly differentiated tumors [74,75]. c-MYC also controls
the production of many non-coding RNAs, including tRNA, rRNA and
miRNAs, and these RNAs are likely to contribute substantially to the
complex biology and pathology that is associated with c-MYC [76,77].
In a pionner study in 2005, J.T. Mendell and coworkers reported
the direct induction of the mir-17-92 cluster by c-MYC [44]. This
cluster of six miRNAs is considered as an oncogene and cooperates
with c-MYC to accelerate tumor development in a mouse model of
B-cell lymphoma [78]. Expression ofmir-17-92 is high in proliferating
cells and this miRNA cluster has also been functionally implicated in
several solid tumors as well as in tumor angiogenesis [52,79]. Thiscluster, as well as the paralogous cluster mir-106a-92-2, are also
induced by MYCN, a transcription factor shown to promote cell cycle
progression in neuroblastoma cells [80]. Other miRNAs were also
induced after overexpression of MYCN in the same study although
direct binding to target promoters was not tested. Both c-MYC and
MYCN also induce miR-9, a miRNA that targets CDH1, the E-cadherin-
encoding mRNA, leading to increased cell motility and invasiveness,
as well as to increased tumor angiogenesis [81].
Despite the relevance of the induction of themir-17-92 cluster and
miR-9 by c-MYC, the activity of this transcription factor has a major
effect as a repressor of many other miRNAs. miRNA expression has
been reported to be globally reduced in tumor samples and inhibition
of miRNA biogenesis accelerates tumorigenesis in vivo [82]. c-MYC
may participate in the tumor-associated repression of miRNAs by
directly repressing several miRNA clusters such asmir-15a-16-1, miR-
22, miR-23a/b, miR-26, miR-29 and several let-7 clusters [83]. Many of
Table 2
Cell cycle-dependent regulation of miRNA expression by transcription factors.
Cell cycle regulator miRNA gene or cluster Relationship References
c-MYC let-7 (several clusters) Repression [83]
mir-9 Induction [81]
mir-15a-16-1 Repression [83]
mir-17-92 Induction [44]
mir-22 Repression [83]
mir-23a-24-2 andmir-23b-24-1 Repression [150]
mir-26a-1 andmir-26a-2 Repression [83]
mir-26b Repression [83]
mir-29b-2-29c and mir-
29b1-29a
Repression [83]
mir-30e-30c-1 Repression [83]
mir-34a Repression [83]
mir-146a Repression [83]
mir-150 Repression [83]
mir-497-195 Repression [83]
MYCN mir-9 Induction [81]
mir-17-92 Induction [80]
mir-106a-92-2 Induction [80]
mir-221-222 Induction [80]
E2Fs (mostly E2F1
and E2F3)
let7a-d Induction [69]
let7i Induction [69]
mir-15b-16-2 Induction [69]
mir-17-92 Induction [44,91]
mir-106b-25 Induction [69]
mir-449c-b-a Induction [95]
p53 mir-34a andmir-34b-/c Induction [98,100–104]
mir-143-145 Induction [106]
mir-194-2-192 Induction [105]
mir-194-1-215 Induction [105]
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sors and target critical cell cycle regulators (Fig. 1 and Table 1). For
instance, the mir-15a-16-1 locus is deleted or downregulated in over
two-thirds of individuals with chronic lymphocytic leukemia [21,84].
On the other hand, the mature miR-15a and miR-16 miRNAs target
several cell cycle genes (Table 1) although since most of these targets
have been validated in other cell types it is not clear two what extent
the anti-tumoral effect of these miRNAs relies in their cell cycle effect.
Several of the other c-MYC-repressed miRNAs also have marked anti-
tumorigenic activity in a mouse model of B cell lymphoma [83].
Although most of these miRNAs are downregulated through the
transcriptional repressor activity of c-MYC, this protein may also lead
to miRNA downregulation by alternative mechanisms. Thus, c-MYC is
able to block the maturation of speciﬁc miRNAs by inducing the RNA
binding proteins Lin28 and Lin28b [85,86], which are known to act as
negative regulators of let-7 maturation at multiple levels including
Drosha and Dicer processing [77]. Repression of multiple miRNAs by
c-MYC is likely to be an important mechanism contributing to the
reduced function of miRNAs in cancer cells [77].3.2. E2F-dependent transcription of miRNAs
The E2F family of transcription factors plays a central role in the
control of cell cycle progression by regulating the timely expression of
genes required for DNA synthesis and mitosis at the G1/S phase
boundary [87–89]. Global gene expression proﬁling and promoter
occupancy studies have conﬁrmed that many proteins crucial for cell
cycle progression are E2F targets [90]. Recent studies have also
reported direct regulation of several miRNAs by E2F transcription
factors. E2F1-3 directly bind the promoter of the mir-17-92 cluster, a
cluster that displays both oncogenic and tumor suppressor activities,
inducing its transcription [91,92]. Since several mir-17-92 miRNAs,
such as miR-17-5p and miR-20a, are able to repress E2F factors [44],
these results suggest an autoregulatory feedback loop that may be
important for preventing an abnormal accumulation of E2F1-3 andproper regulation of cellular proliferation and apoptosis [91,92]. The
mir-106b-25 cluster is also activated by E2F1 in parallel with its host
gene, MCM7. In turn, miR-106b and miR-93 also regulate E2F1
expression, establishing a second miRNA-directed negative feedback
loop [93,94]. E2F1 induces the mir-106b-25 cluster leading to their
accumulation in gastric primary tumors [93]. Themir-449c-b-a cluster
is also a direct transcriptional target of E2F1. These miRNAs are
expressed from the ﬁrst intron of the CDC20B gene and share a
common promoter with the host gene. miR-449a/b target and inhibit
oncogenic CDK6 and CDC25A resulting in pRB dephosphorylation and
cell cycle arrest at G1 phase, revealing a new negative feedback
regulation of the pRB-E2F1 pathway. miR-449a/b expression is
epigenetically repressed in cancer cells, suggesting a tumor suppres-
sor function of miR-449a/b [95].
The overall induction of miRNAs by E2F transcription factors has
been recently analyzed using expression proﬁles and chromatin
immunoprecipitation assays. At least four miRNA clusters, let-7a-d,
let-7i, mir-15b-16-2, and mir-106b-25, are direct targets of E2F1 and
E2F3 during G1/S and are repressed in E2F1/3 null cells [69].
Interestingly, these miRNAs do not contribute to E2F-dependent
entry into S phase but rather inhibit the G1/S transition by targeting
multiple cell cycle regulators and E2F targets. In the absence of these
miRNAs, E2F induces a stronger DNA replication activity that results
in replicative stress and the corresponding DNA damage response
(Fig. 2). Thus, E2F-induced miRNAs contribute to limiting the
cellular responses to E2F activation, thus preventing replicative
stress [69]. Additional miRNAs are also induced by E2F factors during
cell cycle entry although the consequences of this regulation have
not been studied in detail [69]. Given the known function of E2F in
inducing other oncogenic miRNAs such as the mir-17-92 and mir-
221-222 clusters (Fig. 2), control of miRNAs by E2F is likely to play
multiple roles in cell proliferation and in proliferative diseases such
as cancer.
3.3. Stress-mediated induction of miRNAs
The tumor suppressor p53 acts as a transcription factor that
regulates the expression of numerous genes, leading to cell cycle
arrest, apoptosis, and senescence in response to a variety of stress
signals [96]. Among these functions, p53 mediates the cell cycle arrest
in response to DNA damage by transcriptional induction of the CDK
inhibitor p21Cip1.
Several groups reported in 2007 the induction of the miR-34
family (miR34a, b and c) by p53 in response to stress signals [97–104].
p53 directly binds to the promoter of the mir-34a transcript and the
mir-34b-34c cluster, inducing their expression at the transcriptional
level. Ectopic expression of the miR-34 family induces cell cycle arrest
and apoptosis by down-regulating Cyclin D1, Cyclin E2, E2F
transcription factors as well as CDK4 and CDK6 among other proteins
[32,98,103] (Fig. 1 and Table 1). miR-34a is therefore thought to
contribute to a p21Cip1-independent mechanisms through which p53
induces G1 arrest [99].
Two additional clusters of miRNAs, mir-194-2-192 and mir-194-1-
215, are induced by p53, leading to the up-regulation of miR-192,
miR-194, and miR-215 [105]. These miRNAs were detected at high
levels in normal colon tissue but were severely reduced in many colon
cancer samples. On the other hand, miR-192 and its cousin miR-215
can each contribute to p53 activity and p21Cip1 levels. These effects
were partially dependent on the presence of wild-type p53, suggest-
ing that they function as an internal ampliﬁer of p21Cip1 induction by
p53 (Fig. 3). miR-192 and miR-215 are capable of inducing cell cycle
arrest, but they trigger cell death only with lower efﬁciency than miR-
34a [105]. It has been also reported that p53 directly inducesmiR-145,
a miRNA that subsequently represses c-MYC, thus linking p53 with
the downregulation of c-MYC-dependent oncogenic pathways [106]
(Fig. 3). In general, the induction of miRNAs represents an attractive
Fig. 2. A model for the role of miRNAs induced by E2F transcription factors during the
cell cycle. A, Upon mitogenic signaling and during cell cycle entry, E2F factors become
active and induce the transcription of their target protein-coding genes (e.g. Cyclin E) as
well as speciﬁc miRNA clusters (let-7a-7d, let-7i, mir-15b-16-2 and mir-106b-25).
Whereas proteins induced by E2F trigger DNA replication, E2F-induced miRNAs
maintain low levels of cell cycle regulators and E2F targets (e.g. Cyclin E) to limit the
effect of E2F factors and possible to avoid replicative stress. B, In continuously growing
cells, other miRNA clusters such as mir-17-92 and mir-221-222 accumulate and may
participate in maintaining low levels of cell cycle inhibitors such as members of the Cip/
Kip family of CDK inhibitors thus promoting stable proliferation.
Fig. 3.Networks betweenmiRNAs and transcriptional regulators of the cell cycle. Only a
fewmiRNAs are indicated and additional connections between the indicated regulators
have been omitted for clarity.
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proteins observed after p53 activation.
Finally, several miRNAs are repressed by p53 in a E2F-dependent
manner [107]. These miRNAs include the three mir-17-92 paralogous
clusters (mir-17-92-1,mir-106a-92-2 andmir-106b-25) as well asmir-
15b-16-2 and mir-155 [107]. Several of these miRNAs are induced by
E2F1 and E2F3 transcription factors and regulate multiple E2F-target
coding genes [69,107]. Interestingly, the levels of thesemiRNAs do not
signiﬁcantly change upon DNA damage suggesting a speciﬁc link to
the antiproliferative signals induced during senescence.
4. A complex network of interactions between miRNAs and
transcriptional factors
As suggested by the experimental data described in the previous
sections, miRNAs and transcriptional regulators cooperate in multi-
gene transcriptional and post-transcriptional feed-forward (Fig. 3).
p53 can suppress c-MYC at the transcriptional level and the p53
downstream gene, p21Cip1, is able to cause c-MYC repression. On the
other hand, p53 downregulates c-MYC through miR-145 [106]. p53
also represses several miRNAs in a E2F-dependent manner [106,107].
How p53 represses E2F factors is not clear at this moment although it
may be mediated by the p21Cip1- or miR-34a-mediated inhibition of
Cyclin-CDK complexes (Fig. 3).
E2F and c-MYC transcriptional factors also display multiple
connections. E2F1 and c-MYC positively regulate each other and
expression of E2F1 is negatively regulated by twomiRNAs, miR-17-5p
and miR-20a, expressed from themir-17-92 cluster induced by c-MYC
[44] (Fig. 3). Thus, the repression of E2F by these c-MYC-inducedmiRNAs may provide ﬁne-tuning regulation to control the opposing
proliferative and apoptotic functions of E2F. miR-24, which is
repressed by c-MYC [83], is also able to inhibits cell proliferation by
targeting E2F and c-MYC transcription factors, as well as other cell
cycle regulators [62].
The control of miRNAs by E2F transcriptional factors involves
many different interactions that are difﬁcult to understand simply as
proliferative versus antiproliferative functions. On one hand, E2F (as
well as c-MYC) activates the cell cycle proliferation program by
inducing critical cell cycle genes such as cyclins or CDKs. Moreover,
E2F induce the oncogenic mir-17-92, mir-106b-25 and mir-221-222
clusters leading to the downregulation of all members of the Cip/Kip
family of CDK inhibitors (Fig. 3). On the other hand, some of the
miRNAs expressed in these clusters downregulate E2F factors
themselves. In addition, E2F induce antiproliferative miRNAs
expressed by let-7, mir-15b-16-2 or mir-449-c-b-a clusters, which
also downregulate E2F factors as well as many other positive
regulators of the cell cycle. It is now well established that the excess
of proliferative signals may provoke replicate stress and that the
checkpoints that respond to this stress act as an antiproliferative
barrier in cancer [108]. Thus, it is tempting to speculate that the
regulatory loops provide by miRNAs may help preventing replicative
stress induced by proliferative signals [69]. The downregulation of
several of the miRNAs involved in these regulatory loops, such as
members of the let-7 or miR-15 families, could therefore explain the
replicative stress observed in the early phases of tumor development.5. Relevance in human disease/cancer
The relevance of miRNAs to cancer was suggested by changes in
their expression patterns [52,109] and recurrent ampliﬁcation and
deletion of miRNA genes in tumors [21,110]. This has been translated
in several cases into functional validation of roles in tumor initiation
and progression using mouse models and cultured tumor cells.
Several miRNAs have emerged as candidate components of oncogene
and tumor-suppressor networks. The mir-17-92 cluster [44,78], and
miR-155/BIC [111] have been implicated as proto-oncogenes in B-cell
lymphomas. On the other hand, themir-15a-16-1 cluster is frequently
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and evidence from expression studies and functional studies revealed
the potential tumor-suppressive roles of let-7 in various cancers
[112,113], possibly owing to its ability to repress key oncogenic
components, including RAS and HMGA2. Several other miRNAs have
been classiﬁed as oncogenic or tumor-suppressive genes according to
their function in cellular transformation and expression in tumors
[9,10,18,114].
Many of the oncogenic or tumor-suppressor miRNAs target cell
cycle regulators (Table 1) and this interaction may at least partially
explain the oncogenic function of themiRNA alteration in cancer cells.
Themajor oncogenic or tumor-suppressor miRNAs are good examples
of the relevance of targeting the cell cycle for their tumor-related
functions. The ﬁrst oncogenic miRNA gene,mir-17-92, downregulates
p21Cip1 and pRB family members [57,58,115–119] and mir-221-222
exerts it oncogenic function through the downregulation of p27Kip1
and p57Kip2, leading to the activation of Cyclin-CDK complexes and
cell cycle progression [61,120–122]. On the other hand, major tumor-
suppressor miRNAs, such as the members of the let-7 or miR-15
families, downregulate a wide spectrum of positive regulators of the
cell cycle. The cancer growth-suppressive activity of let-7 miRNAs has
since been validated in many human tumors, including colon, lung
and breast cancer [123–126]. In addition to members of the RAS
family, these miRNAs target the cell-cycle regulators CDK4, CDK6,
CDC25A, cyclin D1, D2 and D3, cyclin A or CDC34 as demonstrated by
different techniques [37,82,112,113,127,128]. The miR-15 family
members, miR-15 miR-16 and miR-195, are bona-ﬁde tumor
suppressors and are also master regulators of the cell cycle by
targeting critical regulators such as CDC27, CDK6, Cyclin D1, D3 and E1
or E2F3 factors [23,26,27,129–132]. The involvement of other cell-
cycle targeting miRNAs in human cancer is summarized in Table 1.
6. Conclusions and perspectives
It is now obvious that miRNAs are functionally integrated into
many crucial cell-cycle control pathways. Many miRNAs are anti-
proliferative and this function may be mediated by the control of
different mitogenic pathways including the routes that lead to
activation of CDKs. A few miRNAs induce proliferation in many
cases by targeting CDK inhibitors or members of the pRB family
(Fig. 1). This classiﬁcation is not as simple as some miRNAs, such as
the ones expressed in the mir-17-92 cluster, may target both positive
and negative regulators of the cell cycle (Table 1). In addition, the
control of miRNAs by cell-cycle-dependent transcription factors adds
a new level of complexity. For instance, transcription factors that
positively regulate cell cycle progression, such as c-MYC or E2F family
members, may induce antiproliferative miRNAs to control the extent
of mitogenic signaling and prevent replicative stress (Figs. 2 and 3).
Despite all the knowledge accumulated in the last years, we are
just starting to sense the relevance of miRNAs in cell cycle control and
cell proliferation. Most data summarized in this review comes from
studies with reporter assays, in which the 3′-UTR of one or a few
candidate mRNAs has been placed downstream of the luciferase gene
and this construct is tested after over-expression of wild-type or
mutated forms of the candidate miRNA. Thus, extensive efforts to
develop and improve experimental techniques to show direct target
regulation by miRNAs need to be made. New protocols now exist for
target validation using antisense inhibition of endogenous miRNA
expression using 2-O-Met technology [133], target protectors [134] or
targeted delivery of antisense inhibitor miRNAs [135]. In addition,
most miRNA targets are still unknown due to the lack of reliable
massive techniques suggesting that we aremissing a big portion of the
connections between miRNAs and the cell cycle. Recent papers show
how proteomics technology is a suitable approach to explore the full
impact of miRNAs on protein output and to globally identify their
target genes [136,137]. Finally, it is also important to discuss miRNA–target interactions in a cellular context, as associations of miRNAs and
their targets determined in one cell type may not predict their
association in another cell type. For instance, miR-15a-16 is down-
regulated in prostate cancer, and shares a reciprocal relation with its
targets BCL2, CCND1 and WNT3A in these tumors [23]. However, the
relevant targets of these miRNAs may be different and cannot be
directly taken from studies in other cells types.
In addition, our understanding of regulation of miRNA biogenesis
or function is very limited. For instance, recent data suggest that cell–
cell contact in quiescent cells globally activates miRNA biogenesis
through enhanced processing of miRNAs by Drosha andmore efﬁcient
formation of RNA-induced silencing complexes [138]. How themiRNA
machinery is regulated in a cell-cycle dependent manner is a relevant
question that remains to be analyzed in detail. Some other results on
the control of the miRNA turnover during the cell cycle or the
possibility of a miRNA-dependent activation of translation have
opened new perspectives in the last few years. miR-29b is degraded
in all cell-cycle phases except mitosis while the levels of miR-29a,
which is expressed from the same cluster, are constant [139]. These
data suggest that the stability of miRNAs may be regulated in a cell-
cycle-dependent manner. In addition, miRNAs might have the
potential to up- or down-regulate translation depending on the cell-
cycle stage of the cells. Some miRNAs such as miR-369-3 or let-7
family members may activate translation in quiescent cells while they
repress translation in cycling/proliferating cells [140].
Given the relevance of cell-cycle control in tissue homeostasis and
proliferative diseases, the modulation of cell cycle entry or progres-
sion by miRNAs, and the possible control of miRNA function in a cell-
cycle dependent manner will be the focus of intense research in the
upcoming years. The possible use of miRNAs in therapy [19,20,39]
further highlights the relevance of understanding the connections
between miRNAs and the cell division cycle.
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